KemPharm/$ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
$ZVRA
Sector
Primary listing
Employees
59
Headquarters
Website
KemPharm Metrics
BasicAdvanced
$406M
-
-$0.08
1.56
-
Price and volume
Market cap
$406M
Beta
1.56
52-week high
$13.16
52-week low
$6.19
Average daily volume
1.5M
Financial strength
Current ratio
7.85
Quick ratio
7.661
Long term debt to equity
52.675
Total debt to equity
53.123
Interest coverage (TTM)
-7.12%
Profitability
EBITDA (TTM)
-53.848
Gross margin (TTM)
71.96%
Net profit margin (TTM)
4.26%
Operating margin (TTM)
-97.41%
Effective tax rate (TTM)
87.64%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
-18.85%
Return on equity (TTM)
3.53%
Valuation
Price to revenue (TTM)
6.126
Price to book
3.4
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
-8.166
Free cash flow yield (TTM)
-12.25%
Free cash flow per share (TTM)
-0.885
Growth
Revenue change (TTM)
161.81%
Earnings per share change (TTM)
-95.44%
3-year revenue growth (CAGR)
84.89%
3-year earnings per share growth (CAGR)
-55.32%
10-year earnings per share growth (CAGR)
-53.96%
What the Analysts think about KemPharm
Analyst ratings (Buy, Hold, Sell) for KemPharm stock.
Bulls say / Bears say
Open-label extension data published July 16, 2025 show sustained efficacy and a favorable safety profile for MIPLYFFA® for up to seven years in over 270 NPC patients, highlighting long-term disease stability (GlobeNewswire )
Sale of a Rare Pediatric Disease Priority Review Voucher generated net proceeds of $148.3 million, raising liquidity to $217 million as of Mar. 31, 2025, extending the cash runway into 2029 and strengthening commercial and R&D plans (SEC 10-Q )
The Phase 3 DiSCOVER trial for celiprolol in Vascular Ehlers–Danlos Syndrome has enrolled 32 patients and benefits from both Orphan Drug and Breakthrough Therapy designations, speeding up regulatory review and expanding pipeline value (AInvest.com )
Under-adoption of OLPRUVA® has held back the UCD franchise—with only one new prescription and $300,000 in sales in Q2 2025, significantly missing consensus expectations (Investors.com )
Since launch in July 2023, OLPRUVA® has achieved just 28 total patient enrollment forms through Q1 2025 despite 78% payer coverage, highlighting ongoing commercial challenges (BioSpace )
Zevra’s lead position in NPC is under immediate threat: IntraBio’s AQNEURSA® received FDA approval within days of MIPLYFFA®, intensifying competition for pricing and prescribing (FiercePharma )
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
KemPharm Financial Performance
Revenues and expenses
KemPharm Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $406M as of September 16, 2025.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of September 16, 2025.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.